Sažetak
Apstrakt
Uvod/Cilj. Nova unapređena definicija bolesti suvog oka ističe hiperosmolarnost i upalu sa inicijalnom nestabilnošću suznog omotača kao najčešće etiološke faktore. Cilj rada bio je da se ispita korelacija između nekih često korišćenih kliničkih testova za suvo oko i citološkog nalaza epitela konjuktive dobijenog skrejpingom pri utvrđivanju inflamacije suvog oka. Metode. Od ispitanih 100 bolesnika, dijagnozu suvog oka smo postavili kod 80. Učinjeno je merenje sekrecije suza bez anestezije u 5 minuta Schirmer trakom (Schirmer I), vreme prekida suznog filma obojenog fluoresceinom (Fluorescein Tear Break Up Time – FTBUT), bojenje površine oka vitalnom bojom Rose Bengal (RB). Ispitano je prisustvo nabora konjunktive paralelnih ivica donjeg kapka (Lid-Parallel Conjunctival Folds – LIPCOF), izmerena visina meniskusa suza (Tear Meniscus Height – TMH) i urađen test grananja suze (Tear Ferning – TF). Rezultati. FTBUT je pokazao najvišu senzitivnost (93,6%). Najvišu specifičnost je pokazao RB test (93,2%), ali je visoka specifičnost utvrđena i kod Shirmer I, TF i FTBUT testa (89,8%, 84,5%, 78,0%). Najbolju korelaciju sa citološkim nalazom konjunktivnog skrejpinga imali su RB i FTBUT (r = 0,707, p < 0,001; r = -0.507, p < 0,001). Zaključak. FTBUT iako često korišćen u kombinaciji sa drugim testovima, samostalno je pokazao značajno visoku senzitivnost i specifičnost, kao i dobru korelaciji sa inflamacijom u sklopu bolesti suvog oka citološki detektovanoj skrejpingom konjunktive.
Ključne reči
konjunktiva
citologija
osetljivost i specifičnost
dijagnostički testovi
rutinski
dijagnoza, diferencijalna
Reference
REFERENCES
The definition and classification of dry eye disease: Report of the Definition and Classification Subcommittee of the International Dry Eye WorkShop (2007). Ocul Surf 2007; 5(2): 75–92.
Baudouin C, Aragona P, Messmer EM, Tomlinson A, Calonge M, Boboridis KG, et al. Role of hyperosmolarity in the pathogenesis and management of dry eye disease: proceedings of the OCEAN group meeting. Ocul Surf 2013; 11(4): 246–58.
Aslan Bayhan S, Bayhan HA, Muhafız E, Bekdemir Ş, Gürdal CC. Effects of osmoprotective eye drops on tear osmolarity in contact lens wearers. Can J Ophthalmol 2015; 50(4): 283–9.
Leonardi A, Flamion B, Baudouin C. Keratitis in Dry Eye Disease and Topical Ciclosporin A. Ocul Immunol Inflamm 2017; 25(4): 577–86.
Craig JP, Nichols KK, Akpek EK, Caffery B, Dua HS, Joo CK, et al. TFOS DEWS II Definition and Classification Report. Ocul Surf 2017; 15(3): 276–83.
Versura P, Profazio V, Campos EC. Performance of tear osmo-larity compared to previous diagnostic tests for dry eye diseas-es. Curr Eye Res 2010; 35(7): 553–64.
Sambursky R, Davitt WF, Latkany R, Tauber S, Starr C, Friedberg M, et al. Sensitivity and specificity of a point-of-care matrix metalloproteinase 9 immunoassay for diagnosing inflammation related to dry eye. JAMA Ophthalmol 2013; 131(1): 24–8.
Messmer EM, von Lindenfels V, Garbe A, Kampik A. Matrix Metalloproteinase 9 Testing in Dry Eye Disease Using a Com-mercially Available Point-of-Care Immunoassay. Ophthalmol-ogy 2016; 123(11): 2300–8.
Versura P, Profazio V, Fresina M, Campos EC. A novel scraping cytology score system (SCSS) grades inflammation in dry eye patients. Curr Eye Res 2009; 34(5): 340–6.
Manthorpe R, Oxholm P, Prause JU, Schiødt M. The Copenhagen criteria for Sjögren's syndrome. Scand J Rheumatol Suppl 1986; 61: 19–21.
Höh H, Schirra F, Kienecker C, Ruprecht KW. Lid-parallel con-junctival folds are a sure diagnostic sign of dry eye. Der Oph-thalmologe 1995; 92(6): 802–8. (German)
Michel M, Sickenberger W, Pult H. The effectiveness of questionnaires in the determination of Contact Lens Induced Dry Eye. Ophthalmic Physiol Opt 2009; 29(5): 479–86.
Messmer EM. The pathophysiology, diagnosis, and treatment of dry eye disease. Dtsch Arztebl Int. 2015 Jan 30;112(5):71–81; quiz 82.
Methodologies to diagnose and monitor dry eye disease: report of the Diagnostic Methodology Subcommittee of the Interna-tional Dry Eye WorkShop (2007). Ocul Surf 2007; 5(2): 108–52.
Evans KS, North RV, Purslow C. Tear ferning in contact lens wearers. Ophthalmic Physiol Opt 2009; 29(2): 199–204.
Amparo F, Dastjerdi MH, Okanobo A, Ferrari G, Smaga L, Ha-mrah P, et al. Topical interleukin 1 receptor antagonist for treatment of dry eye disease: A randomized clinical trial. JAMA Ophthalmol 2013; 131(6): 715–23.
Stevenson W, Chauhan SK, Dana R. Dry eye disease: An immune-mediated ocular surface disorder. Arch Ophthalmol 2012; 130(1): 90–100.
Stern ME, Schaumburg CS, Pflugfelder SC. Dry eye as a mucosal autoimmune disease. Int Rev Immunol 2013; 32(1): 19–41.
Calonge M, Enríquez--Salamanca A, Diebold Y, González-García MJ, Reinoso R, Herreras JM, et al. Dry eye disease as an inflam-matory disorder. Ocul Immunol Inflamm 2010; 18(4): 244–53.
Alves M, Reinach PS, Paula JS, Vellasco CA, Bachette L, Faustino J, et al. Comparison of diagnostic tests in distinct well-defined conditions related to dry eye disease. PLoS ONE 2014; 9(5): e97921.
Bartlett JD, Keith MS, Sudharshan L, Snedecor SJ. Associations between signs and symptoms of dry eye disease: A systematic review. Clin Ophthalmol 2015; 9: 1719–30.
Lewis R. New New View of Dry Eye Stresses Mechanisms Over Manifestations. Medscape 2017. Available from:
http://www.medscape.com/viewarticle/879675?nlid=114929_450&src=WNL _mdplsfeat_170516_mscpedit_opth&uac= 159098SY&spon=36&impID=1348993&faf=1#vp_2 [cited 2017 May 8].
Vehof J, Sillevis Smitt-Kamminga N, Nibourg SA, Hammond CJ. Predictors of Discordance between Symptoms and Signs in Dry Eye Disease. Ophthalmology 2017; 124(3): 280–6.